RP 1000

Drug Profile

RP 1000

Alternative Names: RP-1000

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornell University
  • Developer Cornell University; Recro Pharma
  • Class Anaesthetics
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Anaesthesia

Most Recent Events

  • 05 Jul 2017 Phase-I clinical trials in Anaesthesia in USA (IV) before July 2017
  • 05 Jul 2017 Preclinical trials in Anaesthesia in USA (IV) before July 2017
  • 05 Jul 2017 Recro Pharma completes a phase I trial in Anaesthesia in USA (unspecified route) before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top